The rising popularity of GLP-1 drugs could cause all kinds of ripple effects. According to one estimate, 9% of the U.S. population could be on Ozempic or similar medications by 2030. Meanwhile, drugmakers are already developing the next generation of weight-loss drugs and researchers are studying the possible health benefits beyond weight loss and diabetes, including addiction. In the final episode of our series we ask: What could all this development mean for businesses, from the food sector to airlines? And who wins and who loses in the post-Ozempic economy? Guests include: David Ricks, CEO of Eli Lilly; and Mehdi Farokhnia, an addiction researcher at the National Institutes of Health. Listen to Episodes 1, 2 and 3 of “Trillion Dollar Shot” here. Learn more about your ad choices. Visit megaphone.fm/adchoices
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from The Journal.
Transcribed and ready to explore now
Medicare, Inc. Part 1: How Insurers Make Billions From Medicare
06 Jun 2025
The Journal.
Deportations Could Upend This Parachute Factory
05 Jun 2025
The Journal.
The Struggle to Get Aid Into Gaza
04 Jun 2025
The Journal.
The Everyday American Who Hustled for North Korea
03 Jun 2025
The Journal.
Stop Making Cents: The End of the Penny
02 Jun 2025
The Journal.
Ron Howard and Brian Grazer on Longevity in Hollywood
01 Jun 2025
The Journal.